← Eichor
Study identifier: NCT04026360 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Impact of Early Lung Physiology, Viral Infections and the Microbiota on the Development and Progression of Lung Disease in Children With Cystic Fibrosis

Condition: Confirmed Diagnosis of Cystic Fibrosis  ·  Sponsor: Insel Gruppe AG, University Hospital Bern

PhaseN/A
Planned participants500
Who can joinAll sexes, 0 Years to 18 Years
Healthy volunteersNo

About this study

This study collects data on microbiological factors and lung function parameters (e.g. spirometry, body plethysmography, lung-MRI) to assess their interaction on the lung growth and lung development of infants and children with Cystic Fibrosis (CF).

This description comes directly from the study's public registry record.

Talk to the study team

Philipp Latzin, MD PhD  ·  0041 31 632 94 93  ·  philipp.latzin@insel.ch

Always discuss trial participation with your own doctor first.

Locations (1)

University Children's Hospital BernBern, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04026360